Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention

Tewari, Devesh; Nabavi, Seyed Fazel; Sureda, Antoni; Farooqı, Ammad Ahmad; Atanasov, Atanas G.; Vacca, Rosa Anna; Sethi, Gautam; Bishayee, Anupam

doi:10.1016/j.phrs.2017.09.014

Cited by 176 publications

(108 citation statements)

References 115 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…Further, blockade of AP‐1 in combination with palbociclib and fulvestrant was more effective in inhibiting cell growth than dual‐ or mono‐treatment. Various natural products, bioactive phytochemicals, and small molecules targeting AP‐1 are currently under development . However, only one selective c‐Fos/AP‐1 inhibitor (T‐5224), has progressed to phase II clinical trials .…”

Section: Mechanisms Of Resistance To Cdk4/6 Inhibitorsmentioning

confidence: 99%

“…Various natural products, bioactive phytochemicals, and small molecules targeting AP-1 are currently under development. 82 However, only one selective c-Fos/AP-1 inhibitor (T-5224), has progressed to phase II clinical trials. 78 Combining such AP-1 specific inhibitors with CDK4/6 inhibitors may have a synergistic effect in overcoming the acquired resistance to CDK4/6 inhibitors.…”

Section: Cell Cycle-nonspecific Mechanismsmentioning

confidence: 99%

See 1 more Smart Citation

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Pandey

Kim

et al. 2019

Intl Journal of Cancer

240

225

View full text Add to dashboard Cite

Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 inhibitors have been FDA approved: palbociclib, ribociclib and abemaciclib. Despite promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the success of these treatments; therefore, the development of various strategies to overcome this resistance is of great importance. We highlight the various mechanisms that are directly or indirectly responsible for resistance to CDK4/6 inhibitors, categorizing them into two broad groups; cell cycle‐specific mechanisms and cell cycle‐nonspecific mechanisms. Elucidation of the diverse mechanisms through which resistance to CDK4/6 inhibitors occurs, may aid in the design of novel therapeutic strategies to improve patient outcomes. This review summarizes the currently available knowledge regarding mechanisms of resistance to CDK4/6 inhibitors, and possible therapeutic strategies that may overcome this resistance as well.

show abstract

Section: Mechanisms Of Resistance To Cdk4/6 Inhibitorsmentioning

confidence: 99%

Section: Cell Cycle-nonspecific Mechanismsmentioning

confidence: 99%

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Pandey

Kim

et al. 2019

Intl Journal of Cancer

240

225

View full text Add to dashboard Cite

show abstract

“…AP-1 is a key component of various signal transduction pathways, and it regulates various cellular events including proliferation, differentiation, survival, angiogenesis, migration and invasion [146]. The activity of AP-1 is enhanced in numerous human tumor types, thereby playing a key role in tumorigenesis [209].…”

Section: The Role Of Ap-1 In Breast Cancermentioning

confidence: 99%

“…Several compounds, including synthetic inhibitor and bioactive compounds, have been identified based on the mechanism of AP-1 inhibition [209,223]. T-5224 is a selective AP-1 inhibitor initially investigated for the treatment of rheumatoid arthritis in phase II human clinical trials.…”

Section: The Role Of Ap-1 In Breast Cancermentioning

confidence: 99%

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Song

Sinha

et al. 2019

Oncogene

View full text Add to dashboard Cite

show abstract

“…Kinase signaling pathways, including MAP and PI3K/Akt (both upregulated in our study), are associated with oxidation, angiogenesis, cell cycle, and inflammatory cytokines [61][62][63]. In addition, signaling trough toll like receptors triggers an inflammatory reaction [64].…”

Section: Case-cohort Studymentioning

confidence: 59%

Role of miRNAs induced by oxidized low-density lipoproteins in coronary artery disease: the REGICOR Study

Degano

Subirana

García-Mateo

et al. 2019

Preprint

View full text Add to dashboard Cite

Aims: Current risk prediction tools are not accurate enough to identify most individuals at high coronary risk. On the other hand, oxidized low-density lipoproteins (ox-LDLs) and miRNAs are actively involved in atherosclerosis. Our aim was to examine the association of ox-LDL-induced miRNAs with coronary artery disease (CAD), and to assess their predictive capacity of future CAD. Methods and results: Human endothelial and vascular smooth muscle cells were treated with oxidized or native LDLs (nLDL), and their miRNA expression was measured with the miRNA 4.0 array, and analyzed with moderated t-tests. Differently expressed miRNAs and others known to be associated with CAD, were examined in serum samples of 500 acute myocardial infarction (AMI) patients and 500 healthy controls, and baseline serum of 117 incident CAD cases and c 485 randomly-selected cohort participants (case-cohort). Both were developed within the REGICOR AMI Registry and population cohorts from Girona. miRNAs expression in serum was measured with custom OpenArray plates, and analyzed with fold change (age and sex-paired case-control) and survival models (case-cohort). Improvement in discrimination and reclassification by miRNAs was assessed. Twenty-one miRNAs were up- or down-regulated with ox-LDL in cell cultures. One of them, 1 (has-miR-122-5p, fold change=4.85) was upregulated in AMI cases. Of the 28 known CAD-associated miRNAs, 11 were upregulated in AMI cases, and 1 (hsa-miR-143-3p, hazard ratio=0.56 [0.38-0.82]) was associated with CAD incidence and improved reclassification. Conclusion: We identified 2 novel miRNAs associated with ox-LDLs (hsa-miR-193b-5p and hsa-miR-1229-5p), and 1 miRNA that improved reclassification of healthy individuals (hsa-miR-143-3p).

show abstract

Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention

Cited by 176 publications

References 115 publications

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Role of miRNAs induced by oxidized low-density lipoproteins in coronary artery disease: the REGICOR Study

Contact Info

Product

Resources

About